Chemotherapy for the elderly

Aapro M, Köhne CH, Cohen HJ, Extermann M (2005) Never too old? Age should not be a barrier to enrollment in cancer clinical trials. The oncologist 10(3): 198–204

Aapro M (2005) 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 69(2): 7–109

Aapro M, Johnson J (2005) Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours. Gerontology 51(5): 287–296

Alduntag O, DJ Stewart, Fosella FV, et al. (2007) Many patient 80 years or older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2 141–146

Balducci L, Extermann M (2004) Assessment of the older patient with cancer. In, Balducci L, Lyman GH, Ershler WB and Extermann M, Comprehensive Geriatric Oncology, London: Martin Dunitz, 223–235

Bohlius J, Wilson J, Seidenfeld J, et al. (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9,353 patients. J Natl Cancer Inst 98: 708–714

Burns EA, Goodwin JS (2004) Immunological changes of aging. In, Balducci L, Lyman GH, Ershler WB and Extermann M, Comprehensive Geriatric Oncology, London: Martin Dunitz, 158–170

Cohen MA, Lewis GM (2006) Neurotropenic fever. J Emerg Med (2): 227–228

Correale P, Cerretani D, Remondo C (2006) A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16(1): 133–140

Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25: 1824–1831

Extermann M (2006) Treating advanced breast cancer in the older woman. Oncology (Williston Park) 20(11): 1355–1360; discussion 1360, 1362, 1367–8

Gomez Raposo C, Pinto Marin A, Gonzalez Baron M (2006) Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Transl Oncol 8(10): 729–734

Haller DG, Catalano PJ, Macdonald JS, et al. (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of 13 Intergroup 0089. J Clin Oncol 23 8671–8678

Hurria A, Hurria A, Brogan K, et al. (2005) Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 22(9): 785–791

Hutchins LF, Unger JM, Crowley JJ, et al. (1999) Under representation of patients 65 years of age or older in cancer treatments trials. N Engl J Med 341: 2061–2067

Jessup JM, Stewart A, Greene FL, et al. (2005) Adjuvant chemotherapy for stage III colon cancer. JAMA 294: 2703–2711

Kris MG, Hesketh PJ, Somerfield MR, et al. (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18): 2932–2947

Kumar A, Soares HP, Balducci L, et al. (2007) Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted five national cancer sponsorized cooperative groups. J Clin Oncol 25: 1272–1276

Launay-Vacher V, Oudard S, Janus N, et al. (2006) Renal insufficiency in cancer patients: prevalence and implications on anticancer drugs management. Results of the IRMA study. J Clin Oncol ASCO Annual Meeting Proceedings Part I Vol 24, no 18S (June 20 Supplement), 2006: 8603

Lecomte S, Adenis A, Bonneterre J (1994) Anti-emetic treatment and chemotherapy: general review. Rev Med Interne 15(11): 752–769

Leibovici L, Paul M, Cullen M, et al. (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107(8): 1743–1751

Lewis JH, Kilgore ML, Goldman DP, et al. (2003) Participation of patients 65 years of age or older in cancer clinicals trials. J Clin Oncol 21: 1383–1138

Lichtman SM, Wildiers H, Launay-Vacher V, et al. (2007) International Society of Geriatric Oncology recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43: 14–34

Lichtman SM, Wielders H, Chatelut E, et al. (2007) International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients. A analysis of the medical literature. J Clin Oncol 25: 1832–1843

Lichtman SM, Wildiers H, Chatelut E, et al: International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients an analysis of the medical literature. J Clin Oncol 25: 1832–1843

Livi L, Paiar F, Santini R, et al. (2006) Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer. Anticancer Drugs 17(9): 1081–1085

Marty M, Espie M, Llombart A, et al. (2006) Dexrazoxane Study Group. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol 17(4): 614–622

Meta-analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administrations schedule and prognostic factors. J Clin Oncol 16: 3537–3541

NIH Consensus Conference (1990) Adjuvant therapy for patient with colon and rectal cancer. JAMA 264: 1444–1450

Raghavan D, Suh T (2006) Cancer in the elderly population: the protection racket. J Clin Oncol 24: 1795–1796

Saif MW, Elfiky A, Diasio R (2006) Handfoot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 6(3): 219–223

Sargent DJ, Goldberg RM, Jacobson SD, et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patient. N Engl J Med 16: 3537–3541

Schmoll HJ, Arnold D (2006) Update on capecitabine in colorectal cancer. Oncologist 11(9): 1003–1009

Siegelmann-Danieli N, Khandelwal V, Wood GC, et al. (2006) Breast cancer in elderly women: outcome as affected by age, tumor features, comorbidities, and treatment approach. Clin Breast Cancer 7: 59–66

Slimane K, Perez A, Ruffie P, Di Palma M (2004) Management of emesis in cancer patients. Bull Cancer 91(5): 403–408

Smith TJ, Khatcheressian J, Lyman GJ, et al. (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2419: 3187–3205

Stanta G (2004) Morbid anatomy of aging. In, Balducci L, Lyman GH, Ershler WB and Extermann M, Comprehensive Geriatric Oncology, London: Martin Dunitz, 187–193

Talarico L, Cheng G, Pazdur R, et al. (2004) Enrolment of elderly patients in clinical trials for cancer drug registration: a seven-year experience by the US Food and Drug Administration. J Clin Oncol 22 4626–4631

Yancik R, Ries LAG (2000) Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14: 17–23

Yancik R, Wesley MN, Ries LA, et al. (2001) Effect of age and comorbidity in post-menopausal breast cancer patients aged 55 years and older. JAMA 285(7): 885–892